DOAC Uses Rapidly Expand

Dabigatran, apixaban, edoxaban and rivaroxaban all have FDA approval for use to reduce the risk of stroke and blood clots in patients with nonvalvular atrial fibrillation and treatment of deep vein thrombosis and pulmonary embolism. Dabigatran, apixaban and rivaroxaban are also indicated for the prevention of blood clots after hip or knee replacement surgery.